2m 2m 2m 2m 2m 2m 2m
- $8.8BMarket Cap
- 13.20%1-Year Change
- BiotechnologyIndustry
Bio-Techne (TECH)
Key Performance
More- Earnings Score: 60
- Momentum Score: 31
- True Yield: 55
- Financial Health Score: 40
Latest Research & News
S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today
U.S. equities hit fresh record highs on May 6, 2026, with the S&P 500 and Nasdaq 100 reaching all-time peaks. AMD and Super Micro Computer surged 16% on strong AI-driven earnings, while oil prices collapsed 6-7% on diplomatic hopes between Washington and Tehran. Technology stocks led gains, though energy stocks declined sharply. Mixed earnings results saw winners like Flex Ltd. (+30%) and DaVita (+18%), while CDW and Coupang fell 20% and 17.5% respectively.
05/06/2026, 1:35 PM • Benzinga
The global ELISpot & FluoroSpot assay market is projected to grow at a CAGR of 7.1% from 2025 to 2031, driven by increasing adoption of immunology research techniques, personalized immune therapies, and advanced diagnostic assays. Key growth areas include reagent products, pharmaceutical & biotechnology firms, and the APAC region. Major trends include automation, multiplexing capabilities, and expanding applications in clinical diagnostics, vaccine development, and immuno-oncology.
03/20/2026, 7:00 AM • GlobeNewswire
Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.08 per share for the quarter ended December 31, 2025, payable on February 27, 2026, to shareholders of record on February 16, 2026. The company generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide.
02/04/2026, 6:30 AM • Benzinga
The Middle East exosomes market is projected to grow from USD 3.07 million in 2024 to USD 20.03 million by 2033, at a CAGR of 23.38%. Growth is driven by increasing adoption of exosome-based diagnostics and therapeutics, rising biomedical R&D investment, and growing demand for liquid biopsy technologies. Key challenges include stringent regulatory requirements and high manufacturing costs.
01/21/2026, 4:42 AM • GlobeNewswire
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share, payable on November 28, 2025, to shareholders of record on November 17, 2025. The global life sciences company generated over $1.2 billion in net sales in fiscal 2025.
11/05/2025, 6:30 AM • Benzinga
Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne
MDxHealth has completed the acquisition of Exosome Diagnostics from Bio-Techne for $15 million, which includes the ExoDx Prostate test and related assets, with payments structured over four years.
09/15/2025, 5:29 PM • Benzinga
Bio-Techne Stock Upgraded As Analyst Flags Attractive Entry Point
RBC Capital upgraded Bio-Techne to Outperform, raising price target from $61 to $73, citing potential for mid-single-digit revenue growth and attractive valuation after recent market selloff.
09/03/2025, 2:45 PM • Benzinga
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
The global recombinant human hair keratin protein market is experiencing rapid growth, driven by increasing demand in biomedical and cosmetic applications, with North America leading and Asia-Pacific showing the fastest growth potential by 2034.
08/14/2025, 10:00 AM • GlobeNewswire
Bio-Techne (TECH) Q4 EPS Rises 8.2%
Bio-Techne reported Q4 fiscal 2025 earnings with modest revenue beat and non-GAAP EPS growth, but faced challenges including an $83.1 million impairment loss from divesting Exosome Diagnostics and margin pressures in its Diagnostics segment.
08/06/2025, 6:08 PM • The Motley Fool
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share, payable on August 29, 2025, to shareholders of record as of August 18, 2025. The company is a global life sciences organization that generated approximately $1.2 billion in net sales in fiscal 2025.
08/06/2025, 6:30 AM • Benzinga
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Key Executives
- Kim Kelderman
- James T. Hippel
- William A. Geist
- Shane Bohnen
- David Clair
Current Ownership Distribution
- Institutions2.5B (76.49%)
- Mutual Funds755.4M (23.42%)
- Insiders3.1M (0.10%)
- Other0 (0.00%)